SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Company Overview - Rezolute, Inc. is a company listed on NASDAQ under the ticker symbol RZLT [2] - The company is currently facing legal scrutiny due to significant stock losses experienced by investors [2][3] Recent Developments - On December 11, 2025, Rezolute's shares experienced a dramatic decline, dropping approximately 85-90% from a previous close of around $10.94 to an intraday low of approximately $0.90 [4][5] - This sharp decline was triggered by disappointing topline results from its Phase 3 sunRIZE clinical trial for ersodetug, which failed to meet both primary and key secondary endpoints [4] Clinical Trial Results - The Phase 3 clinical trial for ersodetug aimed at treating congenital hyperinsulinism did not show statistically significant reductions in hypoglycemia events compared to placebo [4]